Impact of COVID-19 infection in pregnancy and neonates: A case control study.

Daclin, Camille; Carbonnel, Marie; Rossignol, Manon; Abbou, Hind; Trabelsi, Hela; Cimmino, Aminata; Delmas, Justine; Rifai, Anne-Sophie; Coiquaud, Lou-Andréa; Tiberon, Audrey; Guen, Morgan Le; Ayoubi, Jean-Marc

doi:10.1016/j.jogoh.2022.102366

Cited by 12 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pregnant women included in this study did not develop COVID-19 requiring ICU, nor were there any maternal deaths. This is in line with our department’s experience in the first year of the pandemic, in which we observed a low ICU hospitalization rate of 1.2% for COVID-19 patients [ 28 ]. One of the explanations for this low rate could be a low incidence of associated comorbidities in this patient population.…”

Section: Discussionsupporting

confidence: 90%

Impact of COVID-19 on Subclinical Placental Thrombosis and Maternal Thrombotic Factors

Carbonnel

Daclin

Tourne

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

Background: In the context of the SARS-CoV-2 pandemic, our interest was to evaluate the effect of COVID-19 during pregnancy on placenta and coagulation factors. Methods: a prospective cohort study between January and July 2021 of 55 pregnant women stratified into: Group O, 16 patients with ongoing SARS-CoV-2 infection at delivery; Group R, 21 patients with a history of SARS-CoV-2 infection during pregnancy but who recovered prior to delivery; Group C, 18 control patients with no infection at any time. All women had nasopharyngeal SARS-CoV-2 RT-PCR tests performed within 72 h of delivery. Obstetrical complications were recorded and two physiological inhibitors of coagulation, protein Z (PZ) and dependent protease inhibitor (ZPI), were analyzed in maternal and cord blood. All placentae were analyzed by a pathologist for vascular malperfusion. Results: No patient in any group had a severe COVID-19 infection. More obstetrical complications were observed in Group O (O: n = 6/16 (37%), R: n = 2/21 (10%), C: n = 1/18 (6%), p = 0.03). The incidence of placental vascular malperfusion was similar among the groups (O: n = 9/16 (56%), R: n = 8/21 (42%), C: n = 8/18 (44%), p = 0.68). No PZ or ZPI deficiency was associated with COVID-19. However, an increased ZPI/PZ ratio was observed in neonates of Group R (O: 82.6 (min 41.3–max 743.6), R: 120.7 (29.8–203.5), C: 66.8 (28.2–2043.5), p = 0.04). Conclusion: COVID-19 was associated with more obstetrical complications, but not an increased incidence of placental lesions or PZ and ZPI abnormalities.

show abstract

Section: Discussionsupporting

confidence: 90%

Impact of COVID-19 on Subclinical Placental Thrombosis and Maternal Thrombotic Factors

Carbonnel

Daclin

Tourne

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…As per our main findings, we failed to demonstrate the primary and secondary outcomes of our study, therefore, we failed to demonstrate an association between maternal SARS-CoV-2 infection and HDP. Our results are in line with those of other international studies published in the scientific literature, reporting no increase in the incidence of HDP among SARS-CoV-2 positive pregnant women [19][20][21][22].…”

Section: Interpretation and Hypothesized Explanationsupporting

confidence: 93%

COVID-19 and Hypertensive Disorders of Pregnancy (HDP): A Portuguese Multicentric Retrospective Cohort Study of HDP in SARS-CoV-2 Infected Patients

Mira¹,

Pinho²,

Calado-Araújo³

et al. 2023

Cureus

View full text Add to dashboard Cite

Background: An increased incidence of hypertensive disorders of pregnancy (HDP) has been reported among pregnant women infected by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the pathogen behind coronavirus disease-19 (COVID-19). Although it is primarily a respiratory infection, the extra-pulmonary manifestations of COVID-19 mimic those found in preeclampsia (PE). Moreover, the two conditions share common risk factors and pathological mechanisms, hindering the ability to understand the interaction between them. Current literature on this topic is controversial and as there is an overlap of clinical and laboratory findings, HDP can be an overreported outcome in pregnant women with COVID-19. The aim of our study is to assess whether there is an association between maternal SARS-CoV-2 infection and HDP.Methods: We designed a multicenter retrospective cohort study with data collected from five maternity

show abstract

“…The virus, with an incubation period of ∼5 days (range, 2–14 days), results in symptoms including headaches, fever, diarrhoea, myalgia, cough, severe respiratory illness and death depending on its severity [ 1 ]. Notably, pregnant women and their unborn children are considered high-risk populations, as pregnancy-related infections correlate with a greater risk of morbidity and death [ 2 , 3 ]. In 2020, a total of 3,613,647 births were recorded in the United States, with 225,225 women delivering during the pandemic and approximately 6.9% of these births being affected by COVID-19 [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

The effects of COVID-19 on placental morphology

Heeralall,

Ibrahim,

Lazarus

et al. 2023

Placenta

View full text Add to dashboard Cite

Impact of COVID-19 infection in pregnancy and neonates: A case control study.

Cited by 12 publications

References 29 publications

Impact of COVID-19 on Subclinical Placental Thrombosis and Maternal Thrombotic Factors

Impact of COVID-19 on Subclinical Placental Thrombosis and Maternal Thrombotic Factors

COVID-19 and Hypertensive Disorders of Pregnancy (HDP): A Portuguese Multicentric Retrospective Cohort Study of HDP in SARS-CoV-2 Infected Patients

The effects of COVID-19 on placental morphology

Contact Info

Product

Resources

About